Abbrea Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-1,425
| Closed | -$213K | – | 227 |
|
|
2024
Q1 | $213K | Hold |
1,425
| – | – | 0.03% | 241 |
|
|
2023
Q4 | $273K | Hold |
1,425
| – | – | 0.04% | 207 |
|
|
2023
Q3 | $252K | Hold |
1,425
| – | – | 0.04% | 207 |
|
|
2023
Q2 | $271K | Hold |
1,425
| – | – | 0.04% | 202 |
|
|
2023
Q1 | $285K | Sell |
1,425
-150
| -10% | -$30K | 0.05% | 194 |
|
|
2022
Q4 | $374K | Hold |
1,575
| – | – | 0.07% | 172 |
|
|
2022
Q3 | $315K | Hold |
1,575
| – | – | 0.06% | 174 |
|
|
2022
Q2 | $230K | Hold |
1,575
| – | – | 0.04% | 211 |
|
|
2022
Q1 | $257K | Hold |
1,575
| – | – | 0.04% | 221 |
|
|
2021
Q4 | $267K | Hold |
1,575
| – | – | 0.04% | 218 |
|
|
2021
Q3 | $297K | Hold |
1,575
| – | – | 0.04% | 206 |
|
|
2021
Q2 | $267K | Hold |
1,575
| – | – | 0.04% | 214 |
|
|
2021
Q1 | $222K | Buy |
+1,575
| New | +$222K | 0.04% | 215 |
|